The Effect of MK0633 in Patients With Chronic Asthma (0633-007)

Merck Sharp & Dohme (MSD)

Status and phase: Terminated; Phase 2

Conditions: Asthma

Treatments: Drug: MK0633; Drug: Comparator: placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT00404313

0633-007

2006_553

MK0633-007

Details and patient eligibility

About

A clinical study to evaluate the efficacy and safety of MK0633 in adult patients with chronic asthma.

Enrollment: 688 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Documented clinical history of symptoms of chronic asthma, including dyspnea, wheezing, chest tightness, cough, and/or sputum production
• Males and females 18-70 years of age

Exclusion criteria

• History of kidney or chronic liver disease
• Recent history of heart problems within the past 3 months
• Evidence of another clinically significant, active lung disorder such as bronchiectasis or COPD

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

688 participants in 4 patient groups, including a placebo group

1

Experimental group

Description:

MK0633 10 mg

Treatment:

Drug: MK0633

2

Experimental group

Description:

MK0633 50 mg

Treatment:

Drug: MK0633

3

Experimental group

Description:

MK0633 100 mg

Treatment:

Drug: MK0633

4

Placebo Comparator group

Description:

placebo

Treatment:

Drug: Comparator: placebo